Get the Stockscreener App
21.54
1.27%
0.27
After Hours:
21.54
Vera Therapeutics Inc stock is traded at $21.54, with a volume of 1.93M.
It is up +1.27% in the last 24 hours and down -7.16% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$21.27
Open:
$21.45
24h Volume:
1.93M
Relative Volume:
1.15
Market Cap:
$1.37B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-9.7466
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
+8.84%
1M Performance:
-7.16%
6M Performance:
-21.56%
1Y Performance:
-42.16%
1-Day Range:
$21.27
$21.91
1-Week Range:
$19.28
$22.74
52-Week Range:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
21.54 | 1.36B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Published on: 2025-08-17 09:44:14 - metal.it
Should I average down on Vera Therapeutics Inc. stockMarket Sentiment Report & Stock Market Timing Techniques - newsyoung.net
Vera Therapeutics shares fall 2.84% premarket after announcing inducement grants to new employees. - AInvest
Is Vera Therapeutics Inc. stock a hidden gemSmart Portfolio Allocation - thegnnews.com
Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $53.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
What makes Vera Therapeutics Inc. stock price move sharplyFree Portfolio Health Check - thegnnews.com
Custom watchlist performance reports with Vera Therapeutics Inc.Portfolio Safety Metrics and Return Analysis - Newser
Vera Therapeutics: Equity Incentives and BLA Timelines Signal Confidence in Value Creation - AInvest
HC Wainwright Analysts Lower Earnings Estimates for VERA - Defense World
Cantor Fitzgerald Issues Negative Forecast for VERA Earnings - Defense World
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $53 - 富途牛牛
Vera Therapeutics Inc. stock daily chart insightsTrade Ideas Based on Fundamental Metrics - Newser
Vera Therapeutics Awards Major Stock Package: 99,000 Options, 48,200 RSUs to Expand Team - Stock Titan
Will Vera Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Trend Analysis for Safer Trades - Newser
Wedbush Research Analysts Reduce Earnings Estimates for VERA - Defense World
Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday - Defense World
Can volume confirm reversal in Vera Therapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
Vera Therapeutics Advances Clinical Trials and Financials Amid Progress Toward Commercial Launch - AInvest
Vera Therapeutics Q2 Net Loss Doubles, Revenue at $76.5 Million - AInvest
Vera (VERA) Q2 Net Loss Widens 127% - The Motley Fool
Vera Therapeutics Reports Progress in Clinical Trials - TipRanks
A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $60 to $85 - 富途牛牛
Bkv Corporation shares rise 1.82% after-hours following Vera Therapeutics' positive trial results and upcoming BLA submission. - AInvest
Vera Therapeutics Signs New Sales Agreement with TD Securities - TipRanks
Vera Therapeutics files for offering of up to $200 million Class A Common Stockfiling - MarketScreener
Form 424B5 Vera Therapeutics, Inc. - StreetInsider
Vera Therapeutics sees cash funding operations through launch of atacicept - TipRanks
Vera Therapeutics reports Q2 EPS ($1.20), consensus (62c) - TipRanks
Vera Therapeutics announces anticipated upcoming milestones - TipRanks
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - The Manila Times
Vera Therapeutics Q2 Net Loss Widens - MarketScreener
Trendlines Converge — Decision Point for Vera Therapeutics Inc.Momentum Based Equity Trading Plans Reviewed - metal.it
Vera Therapeutics Shares Fall After Downgrade From Wolfe Research - MarketScreener
Wolfe Research downgrades Vera Therapeutics stock rating on limited catalysts - Investing.com Canada
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research - TipRanks
Vera Therapeutics Inc.’s Price Action Aligns with Quant SignalsFast Exit and Entry Strategy Guide Offered - metal.it
How volatile is Vera Therapeutics Inc. stock compared to the marketAchieve breakthrough financial results today - Jammu Links News
Is Vera Therapeutics Inc. a growth stock or a value stockBuild wealth faster with expert stock selection - Jammu Links News
Is Vera Therapeutics Inc. a good long term investmentAchieve breakthrough profits with expert advice - Jammu Links News
How strong is Vera Therapeutics Inc. company’s balance sheetPowerful profit generation - Jammu Links News
What are the latest earnings results for Vera Therapeutics Inc.Breakthrough wealth creation - Jammu Links News
Vera Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough performance with smart picks - Jammu Links News
What is the dividend policy of Vera Therapeutics Inc. stockBuild your wealth with consistent stock growth - Jammu Links News
What catalysts could drive Vera Therapeutics Inc. stock higher in 2025Discover breakthrough stocks before the crowd - Jammu Links News
What are Vera Therapeutics Inc. company’s key revenue driversStay ahead with daily expert stock picks - Jammu Links News
Does Vera Therapeutics Inc. stock perform well during market downturnsUnlock exclusive trading strategies - Jammu Links News
What is Vera Therapeutics Inc. company’s growth strategyFree Real-Time Stock Data - Jammu Links News
What are the technical indicators suggesting about Vera Therapeutics Inc.Free Buy/Sell Signal Notifications - Jammu Links News
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):